Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Inclusion Criteria: * Biopsy/pathology-proven clear cell renal cell carcinoma (CCRCC) with metastases * Have an Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 * Hemoglobin \>= 10 gm/dL * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L * Platelets \>= 100 x 10\^9/L * Total bilirubin =\< upper limit of normal (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< ULN * International normalization ratio (INR) and activated partial thromboplastin time (aPTT) \< 1.2 x ULN * Serum creatinine \< 1.5 mg/dL or if serum creatinine \> 1.5 mg/dL then calculate creatinine clearance (CrCL) \> 30 mL/min * Urine protein to creatinine ratio =\< 1 (if urine protein creatinine ratio is \> 1, then a 24-hour urine total protein must be assessed; subjects will be ineligible if the 24-hour urine protein is found to be \> 1 gm) * Normal cardiac ejection fraction (\> 50%) by multi gated acquisition scan (MUGA) or echocardiogram * Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present * Ability to swallow and retain oral medication * Subjects of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediate…